Davis A, Smith P, Ferguson M, Stephens D, Gianopoulos I
MRC Hearing and Communication Group, The University of Manchester, UK.
Health Technol Assess. 2007 Oct;11(42):1-294. doi: 10.3310/hta11420.
To show that hearing loss has such a high prevalence in the older population to justify screening, if effective and acceptable methods are available; and that population take-up and benefit can make a measurable outcome difference in quality of life.
A population study of people aged 55-74 years was undertaken. A clinical effectiveness study of differently organised screening programmes was carried out using a controlled trial to identify those who might benefit from intervention (and the extent of the benefit). A retrospective case-control study examined the very long-term (more than 10 years) compliance of patients in using their hearing aids after early identification and determined the extent to which early-identified hearing-impaired people have better outcomes than equivalent people identified later. An examination of the costs and cost-effectiveness of different potential screening programmes was also undertaken.
A population study was designed in the UK, with specific stages being conducted in more depth on a sample of people from Nottingham and Southampton. The clinical effectiveness study was conducted in general practices in Nottingham and Bath using a systematic or opportunistic screen. The retrospective case-control study compared a group of early-identified hearing aid users, with control matched for age, gender and occupation, in Cardiff, Glasgow and Manchester.
In Great Britain responses were obtained for 34,362 individuals from the postal questionnaire as part of a population study, 506 were interviewed, 351 were assessed for benefit from amplification and 87 were fitted with a hearing aid. The clinical effectiveness study received 1461 replies from the first-stage questionnaire screen, with 306 people assessed in the clinic, of whom 156 were fitted with hearing aids. The retrospective case-control study traced 116 previously fitted hearing aid users, who had been identified by a screen, and then conducted a case-control using 50 of these for whom complete data were available, matching with two control groups of 50 people.
The major prospective interventions were to introduce amplification through offering people, with minimal hearing impairment, hearing aid(s) in a rehabilitative setting. In the population study, aids were offered as a monaural in-the-ear (ITE) hearing aid and in the clinical effectiveness study people who met the criteria were randomised to be offered two different ITE hearing aids to be fitted bilaterally. The retrospective case-control study used unilateral and bilateral hearing aids.
Prevalence of hearing problems and degree to which services meet need in 55-74-year age group. Public acceptability and individual benefits of hearing screening and intervention as a function of demographic and hearing domain-specific characteristics. Improvement in quality of life. Screening costs and cost-effectiveness as a function of proposed programmes.
It was found that 12% of people aged 55-74 years have a hearing problem that causes moderate or severe worry, annoyance or upset, 14% have a bilateral hearing impairment of at least 35 dB hearing level (HL) and only 3% currently receive intervention, through the use of hearing aids. Good amplification was shown to benefit about one in four of this 55-74-year-old population and the degree of hearing loss predicted benefit well. Overall, there was a strong correlation between benefit from amplification and from using hearing aids. Questionnaires and audiometric screens gave good screening operating characteristics. The systematic screening programme was more acceptable and gave a better response than the opportunistic. About 70% of those who were offered an aid accepted a bilateral fitting. This increased to 95% for those with > or =35 dB HL (averaged over 0.5, 1, 2 and 4 kHz in the better ear). The retrospective case-control study showed that long-term hearing aid use was low, unless hearing impairment was quite high (e.g. >35 dB HL). Those identified early had greater benefit through additional years of use/better adaptation to use than those of the same age and hearing impairment who were fitted with hearing aids later. Different screening programmes were modelled. The 35 dB HL better ear average hearing impairment level was found to be a good, robust and justifiable target group for screening and here the most efficient and practicable method was to use two questions in primary care concerning hearing problems and a hearing screen using a pure tone at 3 kHz 35 dB HL. The average cost of the screening programme was 13 pounds per person screened or about 100 pounds if treatment costs were included. Making the conservative assumption that identification gives an extra 9 years using hearing aids, the costs of screening and intervention were in the range of 800-1000 pounds per quality-adjusted life-year when using the Health Utilities Index and about 2500 pounds using the Short Form 6 Dimensions metric.
A simple systematic screen, using an audiometric screening instrument, has been shown to be acceptable to people in the age range 55-74 years, is likely to provide substantial benefit and may be cost-effective to those in that target group. Hearing screening appears to meet the National Screening Committee's criteria in most respects, provided screening is targeted at those with at least 35 dB HL better ear average. Based on the research carried out here there is sufficient evidence to support a larger and more definitive study of hearing screening. Further research into who should be referred for and benefit from audiological assessment and provision of hearing aid in a primary care trust setting is needed as is investigation into screening devices and the various aspects of introducing such a programme.
若有有效且可接受的方法,证明听力损失在老年人群中患病率如此之高,足以证明进行筛查的合理性;并证明人群参与度和受益情况能在生活质量方面产生可衡量的结果差异。
对55 - 74岁人群进行了一项人口研究。采用对照试验对不同组织形式的筛查项目进行临床有效性研究,以确定哪些人可能从干预中受益(以及受益程度)。一项回顾性病例对照研究考察了患者在早期确诊后长期(超过10年)使用助听器的依从性,并确定早期确诊的听力受损者比后期确诊的同等患者结局更好的程度。还对不同潜在筛查项目的成本和成本效益进行了考察。
在英国设计了一项人口研究,在诺丁汉和南安普敦的部分人群样本中对特定阶段进行了更深入的研究。临床有效性研究在诺丁汉和巴斯的全科医疗中采用系统或机会性筛查进行。回顾性病例对照研究在加的夫、格拉斯哥和曼彻斯特对一组早期确诊的助听器使用者与年龄、性别和职业匹配的对照组进行了比较。
在英国,作为人口研究的一部分,通过邮政问卷获得了34362人的回复,对506人进行了访谈,对351人进行了放大受益评估,87人佩戴了助听器。临床有效性研究从第一阶段问卷筛查中收到1461份回复,在诊所对306人进行了评估,其中156人佩戴了助听器。回顾性病例对照研究追踪了116名先前通过筛查确诊的佩戴助听器使用者,然后对其中50名有完整数据的使用者进行病例对照研究,并与两个50人的对照组进行匹配。
主要的前瞻性干预措施是在康复环境中为听力受损最小的人提供放大设备,即助听器。在人口研究中,提供的是单耳耳内式(ITE)助听器,在临床有效性研究中,符合标准的人被随机分配提供两种不同的ITE助听器进行双侧佩戴。回顾性病例对照研究使用了单侧和双侧助听器。
55 - 74岁年龄组听力问题的患病率以及服务满足需求的程度。听力筛查和干预的公众可接受性以及作为人口统计学和听力领域特定特征函数的个体受益情况。生活质量的改善。作为拟议项目函数的筛查成本和成本效益。
发现55 - 74岁人群中12%的人存在导致中度或重度担忧、烦恼或困扰的听力问题,14%的人双耳听力损失至少达到35分贝听力水平(HL),目前只有3%的人通过使用助听器接受干预。良好的放大效果显示对该55 - 74岁人群中约四分之一的人有益,听力损失程度能很好地预测受益情况。总体而言,放大受益与使用助听器之间存在很强的相关性。问卷和听力筛查具有良好的筛查操作特征。系统筛查项目比机会性筛查更可接受且回复更好。约70%被提供助听器的人接受了双侧佩戴。对于较好耳平均听力损失≥35分贝HL(在0.5、1、2和4千赫频率平均)的人,这一比例增至95%。回顾性病例对照研究表明,长期使用助听器的情况较少,除非听力损失相当严重(如>35分贝HL)。早期确诊的人通过额外的使用年限/更好地适应使用,比同龄且听力损失相同但后来才佩戴助听器的人受益更大。对不同筛查项目进行了建模。发现较好耳平均听力损失35分贝HL水平是一个用于筛查的良好、稳健且合理的目标群体,在此,最有效且可行的方法是在初级保健中使用两个关于听力问题的问题以及使用3千赫35分贝HL的纯音进行听力筛查。筛查项目的平均成本为每人13英镑,若包括治疗成本则约为100英镑。做出保守假设,即确诊能使使用助听器的时间额外增加9年,使用健康效用指数时,筛查和干预的成本为每质量调整生命年800 - 1000英镑,使用简短健康调查问卷6维度指标时约为2500英镑。
已证明使用听力筛查仪器进行简单的系统筛查在55 - 74岁人群中是可接受的,可能会带来实质性益处,并且对该目标群体可能具有成本效益。听力筛查在大多数方面似乎符合国家筛查委员会的标准,前提是筛查针对较好耳平均听力损失至少为35分贝HL的人群。基于此处开展的研究,有足够证据支持对听力筛查进行更大规模、更具确定性的研究。需要进一步研究在初级保健信托环境中哪些人应被转诊进行听力评估并从助听器提供中受益,以及对筛查设备和引入此类项目的各个方面进行调查。